This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by Soumerai et al¹ regarding the effectiveness of thrombolytic therapy in the elderly was an interesting and important analysis, but, similar to Thiemann et al² in their article questioning the use of thrombolytics in the elderly, they start with the premise that the data of the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group³ (combined data from 9 placebo-controlled thrombolytic trials involving at least 1000 patients) demonstrated only minimal benefit for those older than 75 years. In fact, in the latter study, the data for the elderly was terribly misrepresented because only 5 of the 9 studies (GISSI-1 [Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardio],⁴ ISIS-2 [Second International Study of Infarct Survival Collaborative Group],⁵ ISIS-3 [Third International Study of Infarct Survival Collaborative Study Group],⁶ EMERAS [Estudio Multicentro Estreptoquinsa Republicas de America del Sur],⁷ and LATE [Late Assessment of Thrombolytic Efficacy Study Group]⁸) included significant numbers of elderly . . . [Full Text of this Article]